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Objectives: As key team members caring for people with advanced illness, nurses teach patients 
and families about managing their illnesses and help them to understand their options. Our 
objective was to determine if nurses’ personal healthcare experience with serious illness and 
end-of-life care differs from the general population as has been shown for physicians. 
Design: Observational propensity-matched cohort study 
Setting: Fee-for-service Medicare 
Participants: Nurses’ Health Study (NHS) and a random 20% national sample of Medicare 
beneficiaries aged 66 or older with Alzheimer’s disease and related dementias (ADRD) or 
congestive heart failure diagnosed in hospital (CHF). 
Measurements: Characteristics of care during the first year after diagnosis and the last six 
months of life (EOL). 
Results: Among 57,660 NHS participants, 7,380 had ADRD and 5,375 had CHF; 3,227 ADRD 
patients and 2,899 CHF patients subsequently died. Care patterns in the first year were similar 
for NHS participants and the matched national sample: hospitalization rates, emergency visits 
and preventable hospitalizations were no different in either disease. Ambulatory visits were 
slightly higher for NHS participants than the national sample with ADRD (13.1 vs 12.5 visits, 
p<.01) and with CHF (13.7 vs 12.5, p<.001). Decedents in the NHS and national sample had 
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similar acute care use (hospitalization and emergency visits) in both diseases, but those with 
ADRD were less likely to use life-prolonging treatments such as mechanical ventilation (10.9% 
vs 13.5%, p=.001), less likely to die in a hospital with an ICU stay (10.4% vs 12.1%, p=.03), and 
more likely to use hospice (58.9% vs 54.8%, p<.001). CHF at the EOL results were similar.  
Conclusions: Nurses with newly identified serious illness experience similar care to the general 
Medicare population. However, at the EOL, nurses are more likely to choose less aggressive 
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INTRODUCTION 
People diagnosed with a serious illness face challenging decisions about achieving their 
personal healthcare goals, including how to manage their disease and what care they prefer as 
end of life (EOL) nears. Healthcare professionals have a critical role in helping their patients 
make these decisions. Initiatives, such as the Serious Illness Conversation Guide1, have focused 
efforts on improving clinicians’ ability to engage with patients and their families on this topic. 
Part of that engagement is acknowledging how their own attitudes, experience, and 
preferences may influence what they recommend for others. Therefore, an important aspect of 
improving decisions regarding serious illness is understanding the experience and preferences 
of clinicians regarding their own serious illness. 
Several studies indicate that physicians often prefer care that differs from both what 
they recommend or provide for patients and from what they receive at the end of their own 
lives.2-9 Yet, little attention has focused on nurses, despite their large role in healthcare. Nurses 
often take on the role of educator and spend more time one-on-one with patients and their 
families than other team members, especially in the hospital setting. Nurses have important 
influence on patients’ knowledge about managing their serious illness and understanding their 
options, which is likely informed by their training and their personal attitudes regarding health 
care and EOL.  
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In this study, we compare the type of care received by nurses who participated in the Nurses’ 
Health Study (NHS)10 to the type of care received by similar women in the general Medicare population 
for diseases that have high mortality and may be amenable to chronic disease management and 
advance care planning.  We focused on two serious conditions:  Alzheimer’s Disease and related 
dementias (ADRD) and congestive heart failure (CHF) serious enough to require hospitalization. We 
compared the type of services used during two distinct stages of disease: in the first year after illness 
identification and in the six months prior to death. We hypothesized that due to their clinical training 
and professional exposure to serious illness, nurses would experience better quality care (fewer urgent 
or potentially preventable admissions) and less intensive EOL services. As a secondary analysis, we 
compare the NHS nurses to a general population of men. 
METHODS 
We conducted an observational cohort study in which women participating in the NHS 
cohort who were aged 66 years or older were linked to their Medicare fee-for-service claims 
data; we compared the care of women diagnosed with ADRD and CHF to propensity matched 
cohorts of women drawn from a 20% national sample of fee-for-service Medicare beneficiaries. 
All methods described were repeated for comparison to a similar sample of men. 
Data Sources 
Nurses’ Health Study (NHS). The NHS is based at Brigham and Women’s Hospital in 
Boston, MA. The initial cohort was identified in 1976, when 121,700 female, registered nurses, 
aged 30-55 years living in one of 11 states, returned a mailed questionnaire. Women have been 
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followed for the last 42 years with 90% follow-up. The nurses have since migrated to all 50 
states and aged into Medicare.  
Medicare linkage. In August 2013, NHS participants were notified of the planned 
Medicare linkage and were given the option to “opt-out” of this research; 390 (0.4%) women of 
the 97,729 active NHS participants alive and 65 years or older did so. Participants included in 
this study had to reside in US hospital referral regions (HRRs),11 and be enrolled in fee-for-
service (FFS) Medicare Parts A or B for the relevant observation periods as described below.  
Medicare 20% random sample. The comparator Medicare cohort of women was derived 
from a random 20% sample of all Medicare beneficiaries in the U.S., restricted to residents of 
HRRs where NHS participants reside and to beneficiaries with Parts A and B fee-for-service 
coverage for each period of observation. NHS participants were excluded from the national 
sample. 
Cohort Creation 
For each study sample (NHS participants, 20% national sample of women), we created 
four disease cohorts. The disease cohorts for each sample were identified using only 
information from 2006-2012 Medicare administrative data. First, we identified people newly 
diagnosed with ADRD or with CHF severe enough to require hospitalization.  For ADRD, we 
found the first inpatient or outpatient claim with a diagnostic code included in the Chronic 
Condition Warehouse (CCW) definition and kept cases when no similar claim was found in the 
6 
This article is protected by copyright. All rights reserved.
prior year. For CHF, we used the CCW diagnostic codes found as the primary diagnosis on a 
hospital claim. The reason for requiring hospitalization to enter the cohort was to account for 
the low specificity of CHF diagnoses in claims12-14 and the desire to capture disease cohorts with 
similar risk of death over the observation period. Second, we selected people among the newly 
identified cases who died within our observation period. Once cases were selected, we 
excluded patients for whom we would not be able to observe utilization in the time windows of 
interest (1 year before and after cohort entry and 6 months prior to death) because of changing 
enrollment in Medicare parts A or B, or entry into managed care. 
Outcome Measures 
For the year after a new diagnosis of ADRD or the first hospitalization for CHF, we 
measured use of the hospital, potentially preventable hospitalization, and emergency 
department visits. Additionally, we assessed the volume of ambulatory visits and type of 
specialties visited to assess whether nurses were more likely to access care or specialists. For 
decedents, we measured the place of death, use of hospice, use of life-prolonging treatments 
(including mechanical ventilation, dialysis, and feeding tubes) as well as use of the hospital and 
other types of services in the last 6 months of life.  
Covariates 
Variables used to perform matching were obtained from Medicare administrative data 
including demographics, date of birth and death, race, ZIP code of residence, and health status. 
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ZIP codes were used to identify 2010 US Census Tract median household income and hospital 
referral region (HRR). We measured the number and type of comorbid conditions in the year 
prior to cohort entry by presence of either one inpatient or two outpatient claims seven days 
apart for conditions included in the Elixhauser comorbidity score.15,16  
A covariate not used in matching was nursing home residence. We linked to the 
Minimum Dataset, which includes all nursing home stays, to identify people who -- prior to 
cohort entry -- were long-term nursing home residents based on having spent at least 100 days 
in a nursing home.  
Statistical analysis 
Descriptive analyses of differences between NHS and the 20% Medicare sample of 
women were compared using either two-sided t-tests (for continuous variables) or chi-squared 
tests (for categorical variables). Given expected and observed imbalances in factors such as 
socioeconomics and demographics between the NHS participants and the general population, 
propensity score matching was used to balance observable factors between the study samples. 
Scores were estimated using logistic regression to determine the likelihood that a woman 
would have participated in the NHS, based upon the covariates listed above. 
Propensity score matching was performed using a nearest-neighbor matching algorithm 
to obtain a 1:1 match without replacement between NHS participants and the 20% Medicare 
sample of women. An optimal caliper equal to 0.2 times the standard deviation of the logit of 
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the propensity scores was used to match the logit of the propensity scores, and a 100% match 
was obtained. Finally, the balance in the observable confounders between the NHS participants 
and the matched cohort from the 20% sample was verified using a standardized difference of 
means greater than 0.10 as the minimum threshold for cohorts to be deemed unbalanced for 
that factor.17 
After propensity score matching was complete, outcomes of interest for the NHS and 
the 20% Medicare sample were compared using either two-sided t-tests or chi-squared tests as 
appropriate. All analyses were repeated for comparison to a similarly matched sample of men. 
Analyses were conducted using Stata v14.1 (College Station, TX) and SAS v9.4 (Cary, NC). This 
study was approved by institutional review boards at Brigham and Women’s Hospital and 
Dartmouth College. 
RESULTS 
From the NHS study eligible participants (N=57,660), we identified 7,380 women with 
newly identified ADRD and 5,375 with CHF. Among them, 3,227 with ADRD and 2,899 with CHF 
died by the end of our observation period. Before propensity matching, we compared the NHS 
participants to the national sample of women; NHS participants were more likely to be white, 
less likely to be dually eligible for Medicaid, and lived in higher income ZIP codes (shown in 
Supplementary Table S1 and Supplementary Table S2). There were small differences in age and 
comorbidity count between nurses and the national sample across diagnosis (ADRD or CHF) and 
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stage of disease (newly identified or EOL) cohorts. Once propensity matched, all four cohorts 
were well balanced as shown in Tables 1 and 2.  
Table 3 compares utilization in nurses newly identified with a serious illness compared 
to the matched 20% national sample of similar women in Medicare. In general, acute care use 
was similar with small statistical differences in ambulatory visit rates. In newly identified ADRD, 
hospitalization rates, potentially preventable hospitalizations, and emergency department visits 
were no different between NHS and the national sample. There were no meaningful differences 
when comparing NHS and national sample CHF cohorts (Note: the difference in preventable 
hospitalization rates, .50 vs .54 (p=.02), was statistically significant but unlikely to be clinically 
meaningful). Ambulatory visit rates in both the ADRD and CHF cohorts were approximately 0.5-
1 visit per person higher in nurses compared to the national sample with the difference arising 
from use of specialists, with nurses having more visits to cardiologists and neurologists. 
Acute care use during the last 6 months of life in both the ADRD and CHF cohorts was 
also similar. Hospitalization rates, while statistically different, are clinically close in nurses 
compared to the national sample (1.0 vs. 1.1 per person with ADRD, p=.007 and 1.6 vs 1.7 with 
CHF, p=.04) and had overlapping confidence intervals. Other service use including post-acute 
skilled nursing facility (SNF) stays, emergency visits and ambulatory care visits were no different 
between nurses and the national sample, while home health use in CHF was slightly higher in 
nurses. 
10 
This article is protected by copyright. All rights reserved.
We found differences in treatments used at the end of life and place of death (Table 4 
and Figure 1). In ADRD, nurses were less likely to use life prolonging treatments, including 
ventilator support, dialysis or feeding tubes, compared to the national sample during the last 6 
months of life (10.9% (95% CI 9.82-12.0) vs. 13.5% (95% CI 12.38-14.77), p=.001), less likely to 
have a terminal hospitalization that included an ICU stay (10.4% (95% CI 9.32-11.45) vs. 12.1% 
(95% CI 11.0-13.2), p=.03), and more like to participate in hospice (58.2% (95% CI 56.47-59.91) 
vs. 54.2% (95% CI 52.49-55.96), p=.001). They were also less likely to die in a hospital (16.9% 
(95% CI 15.57-18.15) vs. 19.2% (95% CI 17.85-20.57), p=.014) with a slightly higher proportion 
dying in the community (50.0% (95% CI 48.21-51.69) vs. 47.5% (95% CI 45.77-49.25) p=.05). 
These findings were present in the CHF cohorts with smaller magnitude of difference, with the 
exception that there was no difference between nurses and the general Medicare population of 
women for dying in a hospital with or without an ICU stay. 
While all of the NHS participants were women, we tested whether there may be 
utilization differences between nurses and a matched sample of men (match results in 
Supplementary Table S3 and Supplementary Table S4) and found the same patterns for newly 
identified cases (Supplementary Table S5). At the EOL, nurses had lower hospitalization and 
intensive EOL treatments than men, similar to the comparison to women (Supplementary Table 
S6). Community as a place of death was the same, but men were more likely to die in hospital 
11 
This article is protected by copyright. All rights reserved.
while nurses more likely to die in the nursing home, a difference not observed when comparing 
the nurses to a sample of matched women. 
DISCUSSION 
Nurses are critical team members as primary points of access, educators, and often care 
coordinators for patients with serious illness, a population in particular need of end of life care 
planning. Nurses, like physicians, engage with patients and their families who are making 
important decisions about serious illness. There is a growing literature on the treatment 
physicians receive at the end of their own lives. In this study we focus on nurses as the other 
care team member important for patient and family education. Our main findings are that 
nurses’ utilization is largely similar to the general population except for nurses’ lower use of the 
most intensive services at the EOL and higher use of hospice, particularly for ADRD, which is a 
long, progressive illness. 
Nurses’ education and experience managing people who are ill may lead to personal 
treatment decisions, such as what type of doctor to see or the nature of treatments near the 
end of life, that differ from the general population.  In the case of physicians, several survey 
studies indicate that physicians prefer less aggressive care at the end of life and support use of 
advanced directives.3-5,7,8 No similar survey data on nurses’ preferences is currently available 
although we can examine healthcare received at the EOL. Studies of EOL treatments doctors 
receive have shown they use the hospital similarly to the general population, with perhaps 
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more ICU use, but also more hospice6 and their care is comparable to that of lawyers9 and a 
diverse set of clinicians.2  Our examination of the care nurses receive demonstrates differences 
in specific end of life treatments that are larger and more consistent than those found for 
doctors, including more use of hospice, less use of the ICU during terminal hospitalizations and 
less use of life-prolonging treatments (ventilators, dialysis, or feeding tubes). 
Whereas studies of health utilization among physicians with serious illness have only 
examined the last phase of life, we expanded on this approach, examining health utilization by 
nurses in the year following diagnosis, and at the end of life. We found that nurses do not 
receive better quality of care as measured by preventable hospitalizations and emergency visits 
but are slightly more likely to access specialty care and have more ambulatory visits. It is 
possible that the earlier engagement of disease experts and more ambulatory care could 
contribute to the differences we find at the EOL, which are particularly large in the context of 
ADRD. The differences for CHF are similar to the ADRD results with the exception that nurses do 
not differ from the national sample in use of the ICU during a terminal hospitalization. The 
similarity of nurses to the general population in terminal hospital stay with ICU use may reflect 
the greater likelihood of an acute cardiac event leading to a coronary care unit stay in CHF 
compared to ADRD or from less recognition of CHF as a life-limiting disease in way ADRD is 
recognized.  
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Less aggressive EOL treatments for nurses compared to the general population raises 
the critical question of why the differences occur. A potential explanation is that the work 
experience as nurses informs their personal choices or their advanced care planning. We have 
recently shown that a high proportion (84%) of nurses have advance care planning 
documentation which may empower proxy decisions-makers, as is often necessary with ADRD, 
to direct care toward the nurses’ pre-specified wishes.18  Future studies on how nurses navigate 
the health system when they have serious illness may allow us to leverage those experiences 
and inform development of the nurse educator role to improve advance care planning. While 
nurses may be able to advise during advanced care planning, the current literature suggests 
that this role has been broached only for nurse practitioners, who can practice independently 
of physicians in many states, and for critical care nurses.19-22 Izumi suggests that by not 
accessing the wider nurse workforce we are missing an opportunity to improve advanced care 
planning.23 Yet nurses faces multiple barriers to fulfill this role, including inadequate training, 
lack of role clarity, and the need to work within team hierarchies.23  
This study highlights another important avenue for future research. A potential use of 
the NHS survey data collected over 40 years linked to Medicare data is to study early and mid-
life predictors of health outcomes of women in late life. Our finding that healthcare is similar 
for nurses and the general population except very near death reduces concerns about 
generalizability of these future studies. This application of the NHS data has begun in studies of 
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cancer, preventive care, and cognitive impairment.24-26 Concerns about generalizability also 
motivated comparing to men, in which we found no difference in early disease but larger 
differences at the EOL. EOL care differences between the nurses and men may be driven by 
gender as well as professional healthcare experience. 
This study has important limitations. First, a specific concern is that nurses may be 
diagnosed earlier which could allow more time for advance care planning but we cannot detect 
disease stage using administrative data. This concern, in part, motivated our examination of 
newly identified cases and end-of-life care. The proportion of nurses who die within a year of 
diagnosis  in both ADRD and CHF was slightly lower (1.5-2%) than the general population which 
suggests the nurses may be diagnosed earlier or are healthier, however, these differences were 
not large enough to unbalance the samples. In addition, the NHS and general population 
cohorts were close in age and other illness variables before and after matching, which lowers 
the likelihood that our results are substantively influenced by this potential bias. Second, 
matching was possible only for factors that were measurable in the administrative data; 
therefore, confounding by other unmeasured factors, such as education, could exist. Third, 
although propensity matching makes an internally valid comparison, generalizability to nurses 
and Medicare beneficiaries not represented in this study (such as those enrolled in managed 
care) is potentially limited. Similarly, representation of minorities is low in the parent NHS 
which limits generalizability to minority populations. 
15 
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SUMMARY 
As frontline clinicians, nurses both deliver care and observe firsthand the promises, 
limitations and burdens of medical care. In a national sample of nurses living with serious 
illness, we find that nurses experience similar care to non-nurses in the year following 
diagnosis, but tend to receive less aggressive treatments at the end of life. Incorporating nurses 
into studies of what drives care decisions and how to best support patient decision-making is an 
important, under-tapped opportunity. 
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Figure 1: End of Life Treatments and Place of Death Among NHS and 20% National Sample 
Decedents with ADRD or CHF 
Footnote: * p<.05, ** p<.001, NS non-significant  
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Table 1: Characteristics of NHS Participants and Propensity Matched Women 
from national sample newly identified with ADRD or CHF 
 Newly identified Dementia Newly identified CHF 
  NHS 
participants  




Matched  Std 
diff 
Eligible† beneficiaries 57,660 3,610,529   57,660 3,610,529   
Eligible beneficiaries with 
 
7,380 568,644   5,375 461,632   
Selected beneficiaries 7,380 (100)  7,380 (100)   5,375 (100) 5,375 (100)   
Demographics N (%) unless otherwise indicted 
Age at diagnosis, mean(sd)  80.68 (5.5) 80.75 (6.7) 0.01 80.18 (5.8) 80.23 (7.2) 0.00 
Race             
White 7,123 (96.5) 7,139 (96.7) 0.01 5,207 (96.9) 5,198 (96.7) 0.01 
Black 126 (1.7) 120 (1.6) 0.01 93 (1.7) 108 (2) 0.02 
Hispanic 50 (0.7) 59 (0.8) 0.02 34 (0.6) 28 (0.5) 0.01 
Other 81 (1.1) 62 (0.8) 0.02 41 (0.8) 41 (0.8) 0.01 
Dual eligible for Medicaid 477 (6.5) 444 (6) 0.02 279 (5.2) 275 (5.1) 0.00 











Nursing home resident 659 (8.9) 562 (7.6) 0.07 387 (7.2) 282 (5.2) 0.10 
During 90 days before diagnosis             
Any Nursing home stay 1,111 (15.1) 1,039 (14.1) 0.04 582 (10.8) 522 (9.7) 0.06 
Any Home health services 1,056 (14.3) 1,169 (15.8) 0.05 850 (15.8) 942 (17.5) 0.05 
Any Hospice services 80 (1.1) 79 (1.1) 0.01 24 (0.4) 22 (0.4) 0.01 
During year before diagnosis             
Hospitalizations, mean (sd) 0.92 (1.5) 0.95 (1.5) 0.01 1.65 (1.4) 1.68 (1.5) 0.01 
Ambulatory visits, mean (sd) 24.73 (34.1) 23.75 (32.9) 0.02 26.81 (34.5) 25.42 (34.9) 0.02 
Comorbid conditions             
Comorbidity count, mean (sd) 2.41 (2.3) 2.38 (2.3) 0.00 3.13 (2.4) 3.15 (2.4) 0.00 
Hypertension 4498 (60.9) 4484 (60.8) 0.01 3657 (68) 3720 (69.2) 0.02 
Diabetes 1258 (17) 1257 (17) 0.00 1321 (24.6) 1339 (24.9) 0.01 
Deficiency Anemias            1026 (13.9) 1023 (13.9) 0.00 1078 (20.1) 1110 (20.7) 0.02 
Fluid electrolyte disorders            1046 (14.2) 1020 (13.8) 0.01 936 (17.4) 978 (18.2) 0.02 
Hypothyroidism               1398 (18.9) 1407 (19.1) 0.00 985 (18.3) 960 (17.9) 0.01 
Chronic obstructive lung disease             1074 (14.6) 1053 (14.3) 0.01 1290 (24) 1319 (24.5) 0.01 
Congestive heart failure            773 (10.5) 748 (10.1) 0.02 1316 (24.5) 1311 (24.4) 0.01 
Other neurological disorders             1223 (16.6) 1211 (16.4) 0.00 612 (11.4) 599 (11.1) 0.03 
Depression               761 (10.3) 793 (10.7) 0.01 442 (8.2) 426 (7.9) 0.02 
Renal failure              483 (6.5) 466 (6.3) 0.01 705 (13.1) 702 (13.1) 0.01 
Psychoses               569 (7.7) 576 (7.8) 0.01 272 (5.1) 286 (5.3) 0.00 
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Table 2: Characteristics of NHS Participants and Propensity Matched Women 
from national sample who died with ADRD or CHF 
  EOL Dementia   EOL CHF  
  NHS 
participants   




 Matched   Std 
diff 
 Eligible† beneficiaries  57,660 3,610,529  57,660 3,610,529  
 Eligible beneficiaries with diagnosis  7,380 568,644  5,375 461,632  
 Beneficiaries who died  3,227 3,227  2,899 2,899  
 Died within 1 year of cohort entry  1213 (37.6) 1316 (40.8) 0.06 1532 (52.8) 1576 (54.4) 0.03 
 Demographics  N (%) unless otherwise indicted 
 Age at death, mean(sd)   82.98(5.0) 83.11(6.5) 0.02 81.91(5.4) 81.99(7.0) 0.01 
 Race        
   White  3124 (96.8) 3135 (97.1) 0.01 2803 (96.7) 2803 (96.7) 0.01 
   Black  48 (1.5) 41 (1.3) 0.02 49 (1.7) 48 (1.7) 0.00 
   Hispanic  24 (0.7) 22 (0.7) 0.00 15 (0.5) 15 (0.5) 0.01 
   Other  31 (1) 29 (0.9) 0.00 32 (1.1) 33 (1.1) 0.02 
 Dual eligible for Medicaid  301 (9.3) 300 (9.3) 0.00 195 (6.7) 177 (6.1) 0.03 











 Nursing home resident  429 (13.3) 326 (10.1) 0.11 288 (9.9) 199 (6.9) 0.13 
 During 90 days before diagnosis        
 Any Nursing home stay  701 (21.7) 590 (18.3) 0.09 426 (14.7) 365 (12.6) 0.08 
 Any Home health services  636 (19.7) 644 (20) 0.01 576 (19.9) 639 (22) 0.05 
 Any Hospice services  70 (2.2) 62 (1.9) 0.02 22 (0.8) 29 (1) 0.03 
 During 365 days before diagnosis        
 Hospitalizations, mean (sd)  1.3 (1.8) 1.3 (1.8) 0.01 1.8 (1.6) 1.8 (1.6) 0.00 
 Ambulatory visits, mean (sd)  24.6 (35.6) 23.4 (34.8) 0.02 26.2 (34.8) 22.6 (31.9) 0.06 
 Comorbid Condition count, mean 
(sd)  
2.8 (2.6) 2.7 (2.6) 0.01 3.4 (2.6) 3.4 (2.7) 0.01 
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Table 3: Utilization in year after NHS Participants and Propensity Matched Women from national sample were newly identified 
with ADRD or CHF 
 Dementia  CHF  
  NHS Participants Matched Sample   NHS Participants Matched Sample   
Beneficiaries with diagnosis, n 7,380 7,380  5,375 5,375  
First year utilization, rate per 
person Mean (95% conf int) p-value Mean (95% conf int) p-value 
Hospitalizations  1.1 (1.07-1.15) 1.16 (1.12-1.2) 0.055 2.26 (2.21-2.31) 2.32 (2.27-2.38) 0.077 
Hospital days  17.3 (16.29-18.32) 18.6 (17.53-19.67) 0.084 24.51 (23.51-25.52) 25.12 (24.08-26.16) 0.41 
Potential Preventable 
Hospitalization 
0.14 (0.13-0.15) 0.15 (0.14-0.17) 0.060 0.5 (0.48-0.53) 0.54 (0.52-0.56) 0.018 
Emergency department visits  0.3 (0.29-0.32) 0.3 (0.29-0.31) 0.86 0.29 (0.28-0.32) 0.3 (0.28-0.32) 0.90 
Ambulatory E&M visits 11.35 (11.11-11.6) 10.74 (10.5-12.01) <.001 12.76 (12.42-13.11) 11.85 (11.53-12.18) <0.001 
Primary care visits 6.73 (6.56-6.91) 6.59 (6.43-6.76) 0.25 6.3 (6.09-6.50) 6.25 (6.06-6.46) 0.78 
All Specialty care Visits 4.62 (4.48-4.76) 4.14 (4-4.29) <.001 6.46 (6.24-6.69) 5.59 (5.38-5.81) <.001 
Cardiology visits 0.65 (0.6-0.7) 0.57 (0.53-0.62) 0.019 2.02 (1.92-2.12) 1.79 (1.69-1.89) 0.001 
Psychiatry visits 0.18 (0.15-0.21) 0.17 (0.15-0.2) 0.80 0.06 (0.04-0.09) 0.04 (0.03-0.06) 0.11 
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Table 4: End of Life Utilization and Treatments among NHS Participants and Propensity Matched Women from National Sample 
with ADRD or CHF 
 Dementia  CHF  
  NHS Participants Matched Sample   NHS Participants Matched Sample   
Beneficiaries who died, n 3227 3227  2899 2899  
Utilization during 6 months of life, rate 
per person Mean or % (95% conf int) 
p-
value Mean or % (95% conf int) 
p-
value 
Hospitalizations  1.02 (0.98-1.07) 1.1 (1.06-1.15) 0.007 1.6 (1.54-1.65) 1.67 (1.61-1.72) 0.039 
Hospital days  6.54 (6.21-6.88) 7.24 (6.86-7.63) 0.007 11.7 (11.21-12.2) 12.22 (11.71-12.74) 0.15 
Emergency department visits  0.34 (0.31-0.36) 0.35 (0.33-0.38) 0.35 0.3 (0.3-0.36) 0.34 (0.32-0.37) 0.42 
Skilled nursing facility discharges  0.48 (0.45-0.52) 0.49 (0.46-0.52) 0.81 0.5 (0.51-0.58) 0.57 (0.54-0.61) 0.29 
Skilled nursing facility days  11.96 (11.12-12.81) 12.57 (11.7-53.3) 0.32 11.7 (10.82-12.51) 12.28 (11.4-13.16) 0.32 
Any nursing home stay (skilled or long 
term) (%) 
54.6 (52.86-56.33) 53.3 (55.03-69.32) 0.29 48.4 (46.53-50.2) 46.53 (44.7-48.37) 0.16 
Nursing home days  53.48 (51.05-55.92) 51.39 (49-53.79) 0.23 35.3 (33.23-37.42) 32.67 (30.64-34.7) 0.073 
Any home health service use (%) 33.37 (31.75-35.03) 33.99 (35.66-51.56) 0.60 41 (39.22-42.83) 44.64 (42.82-46.47) 0.005 
Ambulatory E&M visits  7.52 (7.22-7.82) 8.23 (6.91-7.48) 0.12 8.4 (8.13-8.76) 7.82 (7.53-8.13) 0.005 
Location on date of death       
Hospital (%) 16.86 (15.57-18.15) 19.21 (17.85-20.57) 0.014 32.32 (30.62-34.02) 34.18 (32.46-35.91) 0.13 
Skilled nursing facility (%) 8.4 (7.46-9.41) 9.23 (8.26-10.29) 0.24 8.1 (7.17-9.2) 9.52 (8.48-10.65) 0.064 
Long term nursing home (%) 24.05 (22.58-25.56) 23.4 (21.94-24.9) 0.54 13.6 (12.4-14.93) 12.59 (11.4-13.85) 0.24 
Community (%) 49.95 (48.21-51.69) 47.51 (45.77-49.25) 0.049 44.4 (42.61-46.26) 41.77 (39.97-43.59) 0.041 
EOL Treatments       
Any life prolonging treatments* (%) 10.88 (9.82-12) 13.54 (12.38-14.77) 0.001 21.6 (20.14-23.17) 24.15 (22.6-25.75) 0.023 
Terminal Hospitalization with ICU stay (%) 10.35 (9.32-11.45) 12.05 (10.95-13.23) 0.03 22.6 (21.05-24.13) 22.97 (21.45-24.55) 0.71 
Hospice Enrolled in last 30 days of life (%) 58.2 (56.47-59.91) 54.23 (52.49-55.96) 0.001 47.4 (45.56-49.23) 44.46 (42.64-46.29) 0.025 
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*Life prolonging treatments = ventilator, dialysis, feeding tube 
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A. End of Life Treatments
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